engleski

Chronic graft-vs-host disease in 2016: a major challenge and an opportunity

Despite major advances in the treatment of hematological diseases over the last decades, allogeneic hematopoietic stem cell transplantation (alloHSCT) still remains the only curative option for many of them. Chronic GVHD can last for many years causing severe medical, social, and quality of life problems, as well as significantly impacting health- related costs and health care management. cGVHD has been much better characterized using internationally recognized diagnostic criteria and scoring measurements since the first National Institutes of Health (NIH) Consensus classification was developed in 2005 and prospectively validated (3, 6-10). However, there are still plenty of issues in addressing challenges posed by cGVHD to clinicians and academic researchers. To advance this field and break the 30-year-old suboptimal treatment paradigms, the goal is that each cGVHD patient should be either treated in a clinical trial or at least should be documented within a registry capturing essential clinical data on the course of cGVHD. The tools and opportunities to harness cGVHD and create better and safer alloHSCT are in our hands right now.

alloHSCT ; cGVHD ; challenge

nije evidentirano